{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:56:00Z","timestamp":1794020160349,"version":"4.8.0"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec><jats:title>Purpose of review<\/jats:title><jats:p>The purpose of this review is to outline the current understanding of the molecular mechanisms and natural history of osteogenesis imperfecta, and to describe the development of new treatments for this disorder.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent findings<\/jats:title><jats:p>The introduction of next-generation sequencing technology has led to better understanding of the genetic cause of osteogenesis imperfecta and enabled cost-effective and timely diagnosis via expanded gene panels and exome or genome sequencing. Clinically, despite genetic heterogeneity, different forms of osteogenesis imperfecta share similar features that include connective tissue and systemic manifestations in addition to bone fragility. Thus, the goals of treatment in osteogenesis imperfecta extend beyond decreasing the risk of fracture, to include the maximization of growth and mobility, and the management of extraskeletal complications. The standard of care in pediatric patients is bisphosphonates therapy. Ongoing preclinical studies in osteogenesis imperfecta mouse models and clinical studies in individuals with osteogenesis imperfecta have been instrumental in the development of new and targeted therapeutic approaches, such as sclerostin inhibition and transforming growth factor-\u03b2 inhibition.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>Osteogenesis imperfecta is a skeletal dysplasia characterized by bone fragility and extraskeletal manifestations. Better understanding of the mechanisms of osteogenesis imperfecta will enable the development of much needed targeted therapies to improve the outcome in affected individuals.<\/jats:p><\/jats:sec>","DOI":"10.1097\/mop.0000000000000813","type":"journal-article","created":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T13:46:02Z","timestamp":1564407962000},"page":"708-715","source":"Crossref","is-referenced-by-count":152,"title":["Osteogenesis imperfecta: advancements in genetics and treatment"],"prefix":"10.1097","volume":"31","author":[{"given":"Vittoria","family":"Rossi","sequence":"first","affiliation":[{"name":"Department of Molecular and Human Genetics, Baylor College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Molecular and Human Genetics, Baylor College of Medicine"},{"name":"Texas Children's Hospital, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Marom","sequence":"additional","affiliation":[{"name":"Department of Molecular and Human Genetics, Baylor College of Medicine"},{"name":"Texas Children's Hospital, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"17052","DOI":"10.1038\/nrdp.2017.52","article-title":"Osteogenesis imperfecta","volume":"3","author":"Marini","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ajmg.c.31532","article-title":"Pharmacological and biological therapeutic strategies for osteogenesis imperfecta","volume":"172","author":"Marom","year":"2016","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2019.04.021","article-title":"Mendelian bone fragility disorders","volume":"126","author":"Robinson","year":"2019","journal-title":"Bone"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1097\/BPO.0000000000001137","article-title":"Fracture patterns differ between osteogenesis imperfecta and routine pediatric fractures","volume":"38","author":"Peddada","year":"2018","journal-title":"J Pediatr Orthop"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1056\/NEJMp1400788","article-title":"Genotype\u2013phenotype correlation \u2013 promiscuity in the era of next-generation sequencing","volume":"371","author":"Lu","year":"2014","journal-title":"N Engl J Med"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J Med Genet"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s00223-013-9723-9","article-title":"Bone collagen: new clues to its mineralization mechanism from recessive osteogenesis imperfecta","volume":"93","author":"Eyre","year":"2013","journal-title":"Calcif Tissue Int"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"540178","DOI":"10.4061\/2011\/540178","article-title":"Genotype-phenotype correlations in autosomal dominant osteogenesis imperfecta","volume":"2011","author":"Ben Amor","year":"2011","journal-title":"J Osteoporos"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/s41431-019-0373-x","article-title":"Genotype\u2013phenotype correlation study in 364 osteogenesis imperfecta Italian patients","volume":"27","author":"Maioli","year":"2019","journal-title":"Eur J Hum Genet"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1302\/1863-2548.13.180185","article-title":"Complex spine deformities in young patients with severe osteogenesis imperfecta: current concepts review","volume":"13","author":"Castelein","year":"2019","journal-title":"J Child Orthop"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ocl.2018.10.003","article-title":"Osteogenesis imperfecta: a pediatric orthopedic perspective","volume":"50","author":"Franzone","year":"2019","journal-title":"Orthop Clin North Am"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41436-018-0045-1","article-title":"Growth characteristics in individuals with osteogenesis imperfecta in North America: results from a multicenter study","volume":"21","author":"Jain","year":"2019","journal-title":"Genet Med"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/s41436-018-0307-y","article-title":"Longitudinal growth curves for children with classical osteogenesis imperfecta (types III and IV) caused by structural pathogenic variants in type I collagen","volume":"21","author":"Barber","year":"2019","journal-title":"Genet Med"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/1471-2474-15-428","article-title":"Association between joint hypermobility, scoliosis, and cranial base anomalies in paediatric Osteogenesis imperfecta patients: a retrospective cross-sectional study","volume":"15","author":"Arponen","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13023-018-0935-y","article-title":"Oral health-related quality of life in children and adolescents with osteogenesis imperfecta: cross-sectional study","volume":"13","author":"Najirad","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"e0176466","DOI":"10.1371\/journal.pone.0176466","article-title":"Mutations in COL1A1 and COL1A2 and dental aberrations in children and adolescents with osteogenesis imperfecta \u2013 a retrospective cohort study","volume":"12","author":"Andersson","year":"2017","journal-title":"PLoS One"},{"key":"R18-20230918","doi-asserted-by":"crossref","DOI":"10.1016\/j.anorl.2019.05.004","article-title":"Hearing impairment and osteogenesis imperfecta: literature review","author":"Carre","year":"2019","journal-title":"Eur Ann Otorhinolaryngol Head Neck Dis"},{"key":"R19-20230918","first-page":"1","article-title":"Muscle abnormalities in osteogenesis imperfecta","volume":"17","author":"Veilleux","year":"2017","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s11914-018-0456-6","article-title":"Osteogenesis imperfecta: muscle-bone interactions when bi-directionally compromised","volume":"16","author":"Phillips","year":"2018","journal-title":"Curr Osteoporos Rep"},{"key":"R21-20230918","doi-asserted-by":"crossref","DOI":"10.1038\/s41436-019-0491-4","article-title":"Mobility in osteogenesis imperfecta: a multicenter North American study","author":"Kruger","year":"2019","journal-title":"Genet Med"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bone.2019.01.022","article-title":"Aortic aneurysm\/dissection and osteogenesis imperfecta: four new families and review of the literature","volume":"121","author":"Balasubramanian","year":"2019","journal-title":"Bone"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/cge.13440","article-title":"A multicenter study to evaluate pulmonary function in osteogenesis imperfecta","volume":"94","author":"Tam","year":"2018","journal-title":"Clin Genet"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/ppul.24039","article-title":"Ribcage deformity and the altered breathing pattern in children with osteogenesis imperfecta","volume":"53","author":"LoMauro","year":"2018","journal-title":"Pediatr Pulmonol"},{"key":"R25-20230918","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.rehab.2018.02.001","article-title":"Diagnosis, follow-up and management of sleep-disordered breathing in children with osteogenesis imperfecta","volume":"61","author":"Leotard","year":"2018","journal-title":"Ann Phys Rehabil Med"},{"key":"R26-20230918","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13023-019-1004-x","article-title":"Assessing disease experience across the life span for individuals with osteogenesis imperfecta: challenges and opportunities for patient-reported outcomes (PROs) measurement: a pilot study","volume":"14","author":"Tosi","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"R27-20230918","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00198-018-4801-5","article-title":"Health-related quality of life in children with osteogenesis imperfecta: a large-sample study","volume":"30","author":"Song","year":"2019","journal-title":"Osteoporos Int"},{"key":"R28-20230918","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00198-018-4690-7","article-title":"Incorporating the patient perspective in the study of rare bone disease: insights from the osteogenesis imperfecta community","volume":"30","author":"Swezey","year":"2019","journal-title":"Osteoporos Int"},{"key":"R29-20230918","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2147\/JMDH.S113483","article-title":"Managing the patient with osteogenesis imperfecta: a multidisciplinary approach","volume":"10","author":"Marr","year":"2017","journal-title":"J Multidiscip Healthc"},{"key":"R30-20230918","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13023-018-0905-4","article-title":"Consensus statement on physical rehabilitation in children and adolescents with osteogenesis imperfecta","volume":"13","author":"Mueller","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"R31-20230918","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1359\/jbmr.2003.18.2.237","article-title":"Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen","volume":"18","author":"Marini","year":"2003","journal-title":"J Bone Miner Res"},{"key":"R32-20230918","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1530\/EJE-10-0208","article-title":"GH in combination with bisphosphonate treatment in osteogenesis imperfecta","volume":"163","author":"Antoniazzi","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"R33-20230918","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med"},{"key":"R34-20230918","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.matbio.2018.03.010","article-title":"Osteogenesis imperfecta and therapeutics","volume":"71\u201372","author":"Morello","year":"2018","journal-title":"Matrix Biol"},{"key":"R35-20230918","doi-asserted-by":"crossref","first-page":"e10118","DOI":"10.1002\/jbm4.10118","article-title":"A multicenter observational cohort study to evaluate the effects of bisphosphonate exposure on bone mineral density and other health outcomes in osteogenesis imperfecta","volume":"3","author":"Bains","year":"2019","journal-title":"JBMR Plus"},{"key":"R36-20230918","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4158\/EP171910.OR","article-title":"Zoledronic acid versus alendronate in the treatment of children with osteogenesis imperfecta: a 2-year clinical study","volume":"24","author":"Lv","year":"2018","journal-title":"Endocr Pract"},{"key":"R37-20230918","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/s12891-018-2252-y","article-title":"Cyclic bisphosphonate therapy reduces pain and improves physical functioning in children with osteogenesis imperfecta","volume":"19","author":"Garganta","year":"2018","journal-title":"BMC Musculoskelet Disord"},{"key":"R38-20230918","first-page":"CD005088","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"7","author":"Dwan","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R39-20230918","doi-asserted-by":"crossref","first-page":"e894","DOI":"10.1097\/MJT.0000000000000236","article-title":"Efficacy of bisphosphonates on bone mineral density and fracture rate in patients with osteogenesis imperfecta: a systematic review and meta-analysis","volume":"23","author":"Shi","year":"2016","journal-title":"Am J Ther"},{"key":"R40-20230918","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jbmr.2410","article-title":"Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials","volume":"30","author":"Hald","year":"2015","journal-title":"J Bone Miner Res"},{"key":"R41-20230918","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11914-017-0380-1","article-title":"Denosumab: an emerging therapy in pediatric bone disorders","volume":"15","author":"Boyce","year":"2017","journal-title":"Curr Osteoporos Rep"},{"key":"R42-20230918","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/jbmr.2480","article-title":"Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab","volume":"30","author":"Ominsky","year":"2015","journal-title":"J Bone Miner Res"},{"key":"R43-20230918","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s00223-016-0110-1","article-title":"Osteogenesis imperfecta type VI in individuals from Northern Canada","volume":"98","author":"Ward","year":"2016","journal-title":"Calcif Tissue Int"},{"key":"R44-20230918","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13023-014-0145-1","article-title":"Two years\u2019 experience with denosumab for children with osteogenesis imperfecta type VI","volume":"9","author":"Hoyer-Kuhn","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"R45-20230918","first-page":"76","article-title":"Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI","volume":"18","author":"Trejo","year":"2018","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"R46-20230918","first-page":"24","article-title":"Safety and efficacy of denosumab in children with osteogenesis imperfecta \u2013 a first prospective trial","volume":"16","author":"Hoyer-Kuhn","year":"2016","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"R47-20230918","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/apa.14154","article-title":"Systematic review of the effect of denosumab on children with osteogenesis imperfecta showed inconsistent findings","volume":"107","author":"Li","year":"2018","journal-title":"Acta Paediatr"},{"key":"R48-20230918","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1210\/js.2018-00118","article-title":"Osteoanabolic agents for osteoporosis","volume":"2","author":"Haas","year":"2018","journal-title":"J Endocr Soc"},{"key":"R49-20230918","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1\u201334) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol Pathol"},{"key":"R50-20230918","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of teriparatide treatment in adults with osteogenesis imperfecta","volume":"124","author":"Orwoll","year":"2014","journal-title":"J Clin Invest"},{"key":"R51-20230918","doi-asserted-by":"crossref","first-page":"153","DOI":"10.11138\/ccmbm\/2017.14.1.153","article-title":"Efficacy of teriparatide vs neridronate in adults with osteogenesis imperfecta type I: a prospective randomized international clinical study","volume":"14","author":"Leali","year":"2017","journal-title":"Clin Cases Miner Bone Metab"},{"key":"R52-20230918","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bone.2018.10.015","article-title":"Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: results from the ACTIVE phase 3 trial","volume":"120","author":"Miller","year":"2019","journal-title":"Bone"},{"key":"R53-20230918","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bone.2019.04.011","article-title":"Sclerostin antibody reduces long bone fractures in the oim\/oim model of osteogenesis imperfecta","volume":"124","author":"Cardinal","year":"2019","journal-title":"Bone"},{"key":"R54-20230918","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpobgyn.2019.02.007","article-title":"Fetal stem cell transplantation and gene therapy","author":"Sagar","year":"2019","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"R55-20230918","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nm.3544","article-title":"Excessive transforming growth factor-\u03b2 signaling is a common mechanism in osteogenesis imperfecta","volume":"20","author":"Grafe","year":"2014","journal-title":"Nat Med"},{"key":"R56-20230918","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bone.2017.02.004","article-title":"Genetic causes and mechanisms of osteogenesis imperfecta","volume":"102","author":"Lim","year":"2017","journal-title":"Bone"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000000813","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T13:04:43Z","timestamp":1721567083000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000000813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000000813","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}